Transform Cardiovascular Risk in Diabetes (TRANSFORM CVRiD)

What You Will Learn

  • Key considerations and practical application tips from the latest trials
  • Mechanisms of action, indications, dosing, contradictions, cautions, and adverse events for the SGLT2i drugs and GLP-1 RA drugs
  • Practical tips for drug initaition
  • How to implement guideline-directed medical therapy with a care team

We are grateful to these distinguished faculty who contributed to this collection:

Pam R. Taub, MD, FACC (Chair)

 

Laurence S. Sperling, MD, FACC

 

Robert H. Eckel, MD

 

Leigh Perreault, MD

 

Vanita Aroda, MD

 

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES

 

Melissa Magwire, CDE, MSN, RN

 

Neil S. Skolnik, MD 

 

Jandra Hancock, APRN, FNP-C, CDCES

 

Kristin Repp, PharmD

 

Eden Miller, DO

 

Educational Grant Support Provided By: Novo Nordisk | Page Launched: February 2022

Android App Download IOS App Download Powered By